Nature Nanotechnology,
Journal Year:
2024,
Volume and Issue:
19(8), P. 1224 - 1233
Published: May 27, 2024
Abstract
Improved
vaccination
requires
better
delivery
of
antigens
and
activation
the
natural
immune
response.
Here
we
report
a
lipid
nanoparticle
system
with
capacity
to
carry
antigens,
including
mRNA
proteins,
which
is
formed
into
virus-like
structure
by
surface
decoration
spike
demonstrating
application
against
SARS-CoV-2
variants.
The
strategy
uses
S1
protein
from
Omicron
BA.1
on
deliver
XBB.1.
particle
enables
specific
augmentation
mRNAs
expressed
in
human
respiratory
epithelial
cells
macrophages
via
interaction
ACE2
or
DC-SIGN
receptors.
Activation
dendritic
demonstrated
same
receptor
binding.
combination
increases
antibody
response
BALB/c
mice
compared
vaccines
alone.
Our
exploration
mechanism
this
robust
immunity
suggests
it
might
involve
cross-presentation
diverse
subsets
ranging
activated
innate
signals
adaptive
signals.
npj Vaccines,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: April 12, 2023
On
November
7th
and
8th,
2022,
The
National
Institute
of
Allergy
Infectious
Diseases
(NIAID),
part
the
Institutes
Health
(NIH),
Coalition
for
Epidemic
Preparedness
Innovation
(CEPI),
Bill
&
Melinda
Gates
Foundation
(BMGF),
Biomedical
Advanced
Research
Development
Authority
(BARDA),
Wellcome
Trust
hosted
a
virtual
workshop
entitled
"Mucosal
Vaccines
SARS-CoV-2:
Scientific
Gaps
Opportunities."
During
workshop,
researchers
vaccine
developers
from
around
world
discussed
potential
mucosal
vaccines
to
block
SARS-CoV-2
transmission
reviewed
status
research.
Here,
we
summarize
key
challenges
opportunities
in
basic,
translational,
clinical
research
that
were
highlighted
during
meeting.
We
also
provide
recommendations
advance
field
accelerate
development
SARS-CoV-2.
Expert Review of Vaccines,
Journal Year:
2024,
Volume and Issue:
23(1), P. 389 - 408
Published: March 15, 2024
Introduction
Current
vaccines
vary
widely
in
both
their
efficacy
against
infection
and
disease,
the
durability
of
efficacy.
Some
provide
practically
lifelong
protection
with
a
single
dose,
while
others
only
limited
following
annual
boosters.
What
variables
make
vaccine-induced
immune
responses
last?
Can
breakthroughs
these
factors
technologies
help
us
produce
better
fewer
doses?
The
is
now
hot
area
vaccinology
research,
especially
after
COVID-19
lost
luster.
It
has
fueled
discussion
on
eventual
utility
existing
to
society
bolstered
anti-vaxxer
camp.
To
sustain
public
trust
vaccines,
lasting
must
be
developed.
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(2), P. 191 - 191
Published: Feb. 13, 2024
Vaccines
are
essential
tools
to
prevent
infection
and
control
transmission
of
infectious
diseases
that
threaten
public
health.
Most
agents
enter
their
hosts
across
mucosal
surfaces,
which
make
up
key
first
lines
host
defense
against
pathogens.
Mucosal
immune
responses
play
critical
roles
in
provide
durable
better
recall
responses.
Substantial
attention
has
been
focused
on
developing
effective
vaccines
elicit
robust
localized
systemic
by
administration
via
routes.
yield
protection
superior
parenterally
delivered
vaccines.
Beyond
valuable
immunogenicity,
can
be
less
expensive
easier
administer
without
a
need
for
injection
materials
more
highly
trained
personnel.
However,
faces
many
challenges,
much
effort
directed
at
development.
In
this
article,
we
review
the
history
vaccine
development
present
an
overview
compartment
biology
immunity
plays
defending
infection,
knowledge
helped
inform
We
explore
new
progress
design
optimization
novel
approaches
created
improve
efficacy
safety
Cell,
Journal Year:
2024,
Volume and Issue:
187(9), P. 2079 - 2094
Published: April 1, 2024
Several
conceptual
pillars
form
the
foundation
of
modern
immunology,
including
clonal
selection
theory,
antigen
receptor
diversity,
immune
memory,
and
innate
control
adaptive
immunity.
However,
some
immunological
phenomena
cannot
be
explained
by
current
framework.
Thus,
we
still
do
not
know
how
to
design
vaccines
that
would
provide
long-lasting
protective
immunity
against
certain
pathogens,
why
autoimmune
responses
target
antigens
others,
or
response
infection
sometimes
does
more
harm
than
good.
Understanding
these
mysteries
may
require
question
existing
assumptions
develop
test
alternative
explanations.
Immunology
is
increasingly
at
a
point
when,
once
again,
exploring
new
perspectives
becomes
necessity.
Trends in biotechnology,
Journal Year:
2023,
Volume and Issue:
41(11), P. 1417 - 1429
Published: June 15, 2023
mRNA
vaccines
have
won
the
race
for
early
COVID-19
vaccine
approval,
yet
improvements
are
necessary
to
retain
this
leading
role
in
combating
infectious
diseases.
A
next
generation
of
self-amplifying
mRNAs,
also
known
as
replicons,
form
an
ideal
platform.
Replicons
induce
potent
humoral
and
cellular
responses
with
few
adverse
effects
upon
a
minimal,
single-dose
immunization.
Delivery
replicons
is
achieved
virus-like
replicon
particles
(VRPs),
or
nonviral
vehicles
such
liposomes
lipid
nanoparticles.
Here,
we
discuss
innovative
advances,
including
multivalent,
mucosal,
therapeutic
vaccines,
highlight
novelties
design.
As
soon
essential
safety
evaluations
been
resolved,
promising
concept
can
transform
into
widely
applied
clinical
platform
technology
taking
center
stage
pandemic
preparedness.
Cellular and Molecular Immunology,
Journal Year:
2023,
Volume and Issue:
21(2), P. 144 - 158
Published: Nov. 10, 2023
Abstract
The
emergence
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
in
2019
prompted
scientific,
medical,
and
biotech
communities
to
investigate
infection-
vaccine-induced
immune
responses
the
context
this
pathogen.
B-cell
antibody
are
at
center
these
investigations,
as
neutralizing
antibodies
(nAbs)
an
important
correlate
protection
(COP)
from
infection
primary
target
SARS-CoV-2
vaccine
modalities.
In
addition
absolute
levels,
nAb
longevity,
neutralization
breadth,
immunoglobulin
isotype
subtype
composition,
presence
mucosal
sites
have
become
topics
for
scientists
health
policy
makers.
recent
pandemic
was
still
is
a
unique
setting
which
study
de
novo
memory
(MBC)
dynamic
interplay
immunity.
It
also
provided
opportunity
explore
new
platforms,
such
mRNA
or
adenoviral
vector
vaccines,
unprecedented
cohort
sizes.
Combined
with
technological
advances
years,
situation
has
detailed
mechanistic
insights
into
development
but
revealed
some
unexpected
findings.
review,
we
summarize
key
findings
last
2.5
years
regarding
immunity,
believe
significant
value
not
only
future
vaccination
approaches
endemic
settings.
The Lancet Respiratory Medicine,
Journal Year:
2023,
Volume and Issue:
11(12), P. 1075 - 1088
Published: Nov. 16, 2023
The
live-attenuated
influenza
virus
vector-based
intranasal
SARS-CoV-2
vaccine
(dNS1-RBD,
Pneucolin;
Beijing
Wantai
Biological
Pharmacy
Enterprise,
Beijing,
China)
confers
long-lasting
and
broad
protection
in
animal
models
is,
to
our
knowledge,
the
first
COVID-19
mucosal
enter
into
human
trials,
but
its
efficacy
is
still
unknown.
We
aimed
assess
safety
(but
not
immunogenicity)
of
dNS1-RBD
against
COVID-19.
npj Vaccines,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Sept. 25, 2023
Abstract
After
decades
of
work,
several
interventions
to
prevent
severe
respiratory
syncytial
virus
(RSV)
disease
in
high-risk
infant
and
older
adult
populations
have
finally
been
approved.
There
were
many
setbacks
along
the
road
victory.
In
this
review,
I
will
discuss
impact
RSV
on
human
health
how
structure-based
vaccine
design
set
stage
for
numerous
countermeasures
advance
through
late
phase
clinical
evaluation.
While
there
are
still
preclinical
early-stage
trials,
review
focus
products
yielding
long-awaited
efficacy
results.
Finally,
some
challenges
next
steps
needed
declare
a
global
victory
against
RSV.
